|
Volrustomig Clinical Trials
10 actively recruiting trials across 7 locations
▼ -3 trials since June 2026
Also known as: MEDI5752, Other Name: MEDI5752
Pipeline
Phase 1: 1Phase 2: 8Phase 3: 1
Top Sponsors
- AstraZeneca9
- University of Chicago1
Indications
- Cancer10
- Gastric Cancer3
- Lung Cancer3
- Non Small Cell Lung Cancer2
- Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)1
Los Angeles, California4 trials
Phase 2
Phase 2
Phase 2
Phase 2
Birmingham, Alabama1 trial
Scottsdale, Arizona1 trial
Little Rock, Arkansas1 trial
Phase 2
Duarte, California1 trial
Santa Monica, California1 trial
Chicago, Illinois1 trial
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
The University of Chicago
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.